The Icon Bioscience development pipeline consists of a broad portfolio of advanced, biodegradable, sustained-released intraocular pharmaceutical products based on Verisome® drug delivery technology.

Our drug development strategy centers on applying the proprietary and patented Verisome technology to off-patent drug entities having established efficacy and safety profiles, thus significantly reducing development risk and allowing for the more comparably speedy 505(b)(2) approval pathway.  Our pipeline products target several key ophthalmic indications, including but not limited to glaucoma, macular edema, inflammation/infection associated with cataract surgery and age-related macular degeneration (AMD).